Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials.

Posted on March 23, 2015 by David

“An updated systematic review of randomized controlled trials examining cannabinoids in the treatment of chronic non-cancer pain was conducted according to PRISMA guidelines for systematic reviews reporting on health care outcomes.

Eleven trials published since our last review met inclusion criteria.

The quality of the trials was excellent.

Seven of the trials demonstrated a significant analgesic effect.

Several trials also demonstrated improvement in secondary outcomes (e.g., sleep, muscle stiffness and spasticity).

Adverse effects most frequently reported such as fatigue and dizziness were mild to moderate in severity and generally well tolerated.

This review adds further support that currently available cannabinoids are safe, modestly effective analgesics that provide a reasonable therapeutic option in the management of chronic non-cancer pain.”

http://www.ncbi.nlm.nih.gov/pubmed/25796592

http://www.thctotalhealthcare.com/category/pain-2/

Tonic Modulation of Nociceptive Behavior and Allodynia by Cannabinoid Receptors in Formalin Test in Rats.

Posted on February 18, 2015 by David

“Cannabinoids produce anti-nociceptive and anti-hyperalgesic effects in acute, inflammatory and neuropathic pain models.

The current study investigated the role of cannabinoid (CB1 and CB2) receptors in modulating formalin-induced nociceptive behavior and mechanical allodynia in the rat…

The results indicate that CB1 and CB2 receptors mediate a tonically inhibitory action on formalin-induced inflammatory pain, especially long-term allodynia, in bilateral hind paws.”

http://www.ncbi.nlm.nih.gov/pubmed/25687494

http://www.thctotalhealthcare.com/category/pain-2/

Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study.

Posted on December 30, 2014 by David

“There is increasing debate about cannabis use for medical purposes, including for symptomatic treatment of chronic pain. We investigated patterns and correlates of cannabis use in a large community sample of people who had been prescribed opioids for chronic non-cancer pain.

CONCLUSIONS:

Cannabis use for pain relief purposes appears common among people living with chronic non-cancer pain, and users report greater pain relief in combination with opioids than when opioids are used alone.”

http://www.ncbi.nlm.nih.gov/pubmed/25533893

http://www.thctotalhealthcare.com/category/pain-2/

Re-branding cannabis: the next generation of chronic pain medicine?

Posted on December 30, 2014 by David

“The field of pain medicine is at a crossroads given the epidemic of addiction and overdose deaths from prescription opioids. Cannabis and its active ingredients, cannabinoids, are a much safer therapeutic option.

Despite being slowed by legal restrictions and stigma, research continues to show that when used appropriately, cannabis is safe and effective for many forms of chronic pain and other conditions, and has no overdose levels.

Current literature indicates many chronic pain patients could be treated with cannabis alone or with lower doses of opioids.

To make progress, cannabis needs to be re-branded as a legitimate medicine and rescheduled to a more pharmacologically justifiable class of compounds.

This paper discusses the data supporting re-branding and rescheduling of cannabis.”

http://www.ncbi.nlm.nih.gov/pubmed/25537695

http://www.thctotalhealthcare.com/category/chronic-pain/

Treatment with a Heme Oxygenase 1 Inducer Enhances the Antinociceptive Effects of µ-Opioid, δ-Opioid, and Cannabinoid 2 Receptors during Inflammatory Pain.

Posted on September 11, 2014 by David

“The administration of µ-opioid receptor (MOR), δ-opioid receptor (DOR), and cannabinoid 2 receptor (CB2R) agonists attenuates inflammatory pain.

We investigated whether treatment with the heme oxygenase 1 (HO-1) inducer, cobalt protoporphyrin IX (CoPP), could modulate the local effects and expression of MOR, DOR, or CB2R during chronic inflammatory pain…

This study shows that the HO-1 inducer (CoPP) increased the local antinociceptive effects of MOR, DOR, and CB2R agonists during inflammatory pain by altering the peripheral expression of MOR and DOR.

Therefore, the coadministration of CoPP with local morphine, DPDPE, or JWH-015 may be a good strategy for the management of chronic inflammatory pain.”

http://www.ncbi.nlm.nih.gov/pubmed/25204546

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study.

Posted on August 16, 2014 by David

“Chronic neuropathic pain is often refractory to standard pharmacological treatments.

Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a “main stream” pharmacological treatment for neuropathic pain.

The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis…

This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.”

http://www.ncbi.nlm.nih.gov/pubmed/25118789

http://www.thctotalhealthcare.com/category/neuropathic-pain/

Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats.

Posted on July 1, 2014 by David

“Resistance exercise (RE) is also known as strength training, and it is performed to increase the strength and mass of muscles, bone strength, and metabolism. RE has been increasingly prescribed for pain relief. However, the endogenous mechanisms underlying this antinociceptive effect are still largely unexplored. Thus, we investigated the involvement of the endocannabinoid system in RE-induced antinociception…

The present study suggests that a single session of RE activates the endocannabinoid system to induce antinociception.”

http://www.ncbi.nlm.nih.gov/pubmed/24977916

Cannabis very effective as painkiller after a major sugery

Posted on June 22, 2014 by David

Fight For medical Marijuana

“The very existence of cannabis as a substance with possible medical use is a contentious topic, to say the least. Its status as an illicit substance is hotly debated, with proponents from both sides (for and against legalization) engaged in a decades-long battle.

The status of marijuana in the United States as a Schedule I Substance under the Controlled Substances Act means not only that it is highly illegal to possess, but it is classified along the likes of cocaine, heroine, and crystal meth.

Schedule I substances are those that a) have high potential to be abused; b) have no currently accepted medical use in treatment in the United States; and c) are lacking in accepted safety in use under medical supervision.

All of these qualifiers are potentially important in classifying drugs and substances, but many people argue that marijuana does not belong in Schedule I…

Pain after surgery remains a problem in the medical community, and traditional prescribed painkillers often have unpleasant side effects as well as diminishing benefits.

Cannabis extracts work due to the cannabinoid receptors in the human brain.

Cannabinoids from marijuana help to effectively strengthen the body’s ability to reduce pain sensation.”

http://www.royalqueenseeds.com/blog-cannabis-very-effective-as-painkiller-after-a-major-sugery–n55

Cannabis very effective as painkiller after a major sugery